- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Joseph Biggio Discusses Ochsner Health's Connected MOM Program, COVID-19 Pregnancy Challenges
At Ochsner Health, the largest nonprofit academic health care system in Louisiana, providers are leveraging the system’s Connected Maternity Online Monitoring (MOM) digital medicine program to minimize expectant mothers’ risks of contracting COVID-19.
As the coronavirus disease 2019 (COVID-19) continues to spread throughout the country, practices and health systems are transforming care to limit exposure to those who may be at greater risk of severe complications. At Ochsner Health, the largest nonprofit academic health care system in Louisiana, providers are leveraging the system’s Connected Maternity Online Monitoring (MOM) digital medicine program to minimize expectant mothers’ risks of contracting COVID-19.
To learn more about this program, we spoke with Joseph Biggio Jr, MD, MS, the system co-chair of Women’s Services and system chair for Maternal-Fetal Medicine at Ochsner Health. Dr Biggio, an obstetrician gynecologist, specializes in provision of high-risk pregnancy care and has been involved with provision of care related to women with medical complications, obstetric complications, and fetal complications in pregnancy.
On this episode of Managed Care Cast, Dr Biggio explains how the Connected MOM program functions and lays out the challenges expectant mothers face during a pandemic.
Listen above or through one of these podcast services:
Leveraging AI and Community Health Workers to Boost Trial Access
January 4th 2025In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community health workers to increasing clinical trial access and how technology—artificial intelligence (AI), in particular—can help to facilitate the process.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
